Market Overview - On September 26, the Traditional Chinese Medicine (TCM) sector declined by 0.38%, with Weikang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Notable gainers in the TCM sector included: - *ST Changyao: Closed at 3.88, up 3.47% with a trading volume of 134,100 shares [1] - Fangsheng Pharmaceutical: Closed at 12.08, up 2.11% with a trading volume of 274,600 shares [1] - Huaren Sanjiu: Closed at 28.39, up 1.50% with a trading volume of 133,600 shares [1] - Major decliners included: - Weikang Pharmaceutical: Closed at 23.66, down 6.30% with a trading volume of 81,000 shares [2] - Zhendong Pharmaceutical: Closed at 6.57, down 4.09% with a trading volume of 518,000 shares [2] - Zhongsheng Pharmaceutical: Closed at 17.00, down 2.41% with a trading volume of 295,000 shares [2] Capital Flow - The TCM sector experienced a net outflow of 298 million yuan from institutional investors, while retail investors saw a net inflow of 396 million yuan [2] - Key stocks with significant capital flow included: - Huaren Sanjiu: Net inflow of 44.98 million yuan from institutional investors [3] - Fangsheng Pharmaceutical: Net inflow of 33.39 million yuan from institutional investors [3] - Dong'e Ejiao: Net inflow of 32.19 million yuan from institutional investors [3]

Core Viewpoint - Fangsheng Pharmaceutical has shown a positive stock performance with a year-to-date increase of 20.68% and a recent surge of 12.06% over the past five trading days, indicating strong market interest and potential growth in the pharmaceutical sector [1][2]. Financial Performance - For the first half of 2025, Fangsheng Pharmaceutical reported a revenue of 834 million yuan, a year-on-year decrease of 8.35%, while the net profit attributable to shareholders increased by 23.67% to 169 million yuan [2]. - The company has distributed a total of 689 million yuan in dividends since its A-share listing, with 444 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 33,100, with an average of 13,245 circulating shares per person, a slight decrease of 0.36% [2]. - The top ten circulating shareholders include notable institutional investors, with ICBC Medical Health Stock holding 5.40 million shares, unchanged from the previous period, and Rongtong Health Industry Flexible Allocation Mixed Fund increasing its holdings by 500,000 shares to 5 million [3]. Market Activity - On September 26, Fangsheng Pharmaceutical's stock price rose by 2.11% to 12.08 yuan per share, with a trading volume of 125 million yuan and a turnover rate of 2.42%, resulting in a total market capitalization of 5.304 billion yuan [1]. - The net inflow of main funds was 4.67 million yuan, with significant buying activity from large orders, indicating strong investor interest [1].

证券之星消息，9月24日中药板块较上一交易日下跌0.28%，维康药业领跌。当日上证指数报收于 3853.64，上涨0.83%。深证成指报收于13356.14，上涨1.8%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | 6.60 | 4.27% | 21.58万 | | 1.41亿 | | 600129 | 太极集团 | 21.75 | 3.97% | 16.50万 | | 3.54Z | | 603998 | 方盛制药 | 11.83 | 3.23% | 44.30万 | | 5.23亿 | | 300181 | 佐力药业 | 18.09 | 3.02% | 17.62万 | | 3.17亿 | | 000423 | 东阿阿胶 | 48.10 | 2.69% | 10.18万 | | 4.87亿 | | 600329 | 达仁堂 | 45.08 | 2.69% | 7.64万 | | 3.43亿 | | 300534 | ...

Group 1 - The core viewpoint of the news is that Fangsheng Pharmaceutical has announced the completion of a Phase II clinical trial summary report for Zhilong Tongluo Tablets, which are indicated for the treatment of ischemic stroke recovery and related symptoms [1][2] - The clinical trial involved 240 planned participants, with 214 actually enrolled, and utilized a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Zhilong Tongluo Tablets [1] - The trial results indicated that Zhilong Tongluo Tablets improved neurological function and daily living abilities, showing effectiveness in treating symptoms associated with ischemic stroke, with no significant safety concerns reported [2] Group 2 - Zhilong Tongluo Tablets are classified as a Class 1 innovative traditional Chinese medicine and are currently the exclusive product of the company, with no other enterprises having obtained production approval for this product [2] - The market for traditional Chinese medicine treatments for stroke includes several products such as Naoxintong Capsules and Tongxinluo Capsules, indicating a competitive landscape [2]

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced the completion of the Phase II clinical trial report for its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, which is aimed at treating ischemic stroke recovery [1][2]. Group 1: Basic Information - Drug Name: Zhilong Tongluo Tablets - Dosage Form: Tablets - Research Type: Phase II Clinical Trial - Clinical Approval Number: 2011L01961 - Clinical Approval Date: November 5, 2011 - Cumulative R&D Expenditure: Approximately 13.566 million RMB (unaudited) [1]. - Indication: Aims to invigorate qi and blood, dispel stasis, and is suitable for treating symptoms related to ischemic stroke recovery [1]. Group 2: Clinical Research Details - The clinical trial was conducted at seven national drug clinical trial institutions across various provinces, with a total of 240 planned participants, of which 214 were actually enrolled [2][3]. - The trial design was randomized, double-blind, and included a placebo control, with participants divided into high-dose (7.5g/day), low-dose (4.5g/day), and placebo groups, receiving treatment for 12 weeks [3]. Group 3: Clinical Research Results - Efficacy results indicated that both high and low doses of Zhilong Tongluo Tablets showed better outcomes compared to the placebo in terms of the Modified Rankin Scale, NIHSS score changes, and quality of life measures [4]. - Safety results showed no significant differences in severe adverse events among groups, with all serious adverse events related to acute stroke recurrence, indicating good safety [4]. - The low-dose group is recommended to proceed to Phase III clinical research due to comparable efficacy with the high-dose group [4]. Group 4: Market Situation - Zhilong Tongluo Tablets are classified as a Class 1 innovative traditional Chinese medicine and are currently the company's exclusive product, with no other companies having obtained production approval for this product [5]. - Other traditional Chinese medicines for treating ischemic stroke include various products with significant sales figures, indicating a competitive market landscape [5].

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced that its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, has obtained the Phase II clinical trial summary report, indicating progress in its development for treating ischemic stroke recovery [1][3]. Group 1: Basic Information - Drug Name: Zhilong Tongluo Tablets - Dosage Form: Tablets - Research Type: Phase II Clinical Trial - Clinical Approval Number: 2011L01961 - Clinical Approval Date: November 5, 2011 - Cumulative R&D Expenditure: Approximately 13.566 million RMB (unaudited) [1][2]. - Indication: Aimed at treating ischemic stroke recovery symptoms such as numbness, pain, and fatigue [1]. Group 2: Clinical Research Details - The Phase II clinical trial was conducted across seven national drug clinical trial institutions in Tianjin, Guangxi, Liaoning, Sichuan, Heilongjiang, and Anhui, with a total of 240 planned participants, of which 214 were actually enrolled [2][4]. - The trial design was randomized, double-blind, and included a placebo control, with participants assigned to high-dose (7.5g/day), low-dose (4.5g/day), and placebo groups [4]. Group 3: Clinical Results - The trial results indicated that both high and low doses of Zhilong Tongluo Tablets showed better efficacy compared to the placebo in improving neurological function and quality of life, with no significant difference in safety across groups [4][5]. - The low-dose group demonstrated comparable efficacy to the high-dose group, suggesting it may be suitable for further Phase III clinical research [5]. Group 4: Market Context - Zhilong Tongluo Tablets are classified as a Class 1 innovative traditional Chinese medicine and are currently the company's exclusive product, with no other companies holding production approval for it [6]. - Competing traditional Chinese medicines for treating ischemic stroke include Naoxin Tong Capsules and Tongxinluo Capsules, with reported sales figures for 2024 indicating significant market presence for these products [6].

Core Viewpoint - Fangsheng Pharmaceutical announced that its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, has obtained the Phase II clinical research report as of September 22, 2025 [2] Company Summary - Fangsheng Pharmaceutical released an announcement regarding the progress of its research and development efforts [2] - The company is focusing on innovative traditional Chinese medicine, indicating a strategic direction towards enhancing its product pipeline [2] Industry Summary - The announcement reflects ongoing developments in the traditional Chinese medicine sector, particularly in the context of clinical research and innovation [2] - The successful completion of Phase II clinical trials is a significant milestone that may influence market perceptions and investment interest in the traditional Chinese medicine industry [2]

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced the completion of Phase II clinical research for its innovative traditional Chinese medicine, Zhilong Tongluo Pian, which shows promising results for treating ischemic stroke recovery [1] Group 1: Clinical Research Findings - The drug is indicated for conditions such as post-stroke recovery, including symptoms like hemiplegia, speech difficulties, and fatigue [1] - Safety results indicate no statistically significant differences in severe adverse events or reactions among groups, with all severe events related to acute stroke recurrence and no fatalities reported [1] - Zhilong Tongluo Pian demonstrated effectiveness in improving the Rankin scale for disability, enhancing neurological function, and increasing daily living capabilities [1] Group 2: Efficacy and Recommendations - The drug is effective for symptoms related to blood stasis and Qi deficiency, including upper limb paralysis and fatigue, with a trend towards efficacy in lower limb paralysis and speech difficulties [1] - Both low-dose and high-dose groups showed comparable efficacy, with a recommendation to continue Phase III clinical research for the low-dose group [1]

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2025-082 湖南方盛制药股份有限公司 关于蛭龙通络片获得II期临床试验总结报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 9 月 22 日，湖南方盛制药股份有限公司（以下简称 "公司"）研发的中药创新药蛭龙通络片取得了 II 期临床研究报 告。为保证所有投资者获取信息的公平、准确、完整，并及时了 解公司经营动态，根据上海证券交易所《上市公司行业信息披露 指引第六号——医药制造》相关规定，公司现将有关内容公告如 下： 一、基本情况 药品名称：蛭龙通络片 剂型：片剂 研究类型：II 期临床试验 临床批件号：2011L01961 获得临床批复时间：2011 年 11 月 5 日 公司于 2013 年 6 月受让北京同御康泰科技有限公司的蛭龙 通络片临床试验批件、处方、生产工艺、质量标准等相关原始研 究资料和技术。2014 年 5 月 20 日， ...

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced the completion of Phase II clinical research for its innovative traditional Chinese medicine, Zhilong Tongluo Pian, which shows promising results for treating ischemic stroke recovery [1] Group 1: Clinical Research Findings - The drug is indicated for conditions such as post-stroke recovery, including symptoms like hemiplegia, speech difficulties, and fatigue [1] - Safety results indicate no statistically significant differences in severe adverse events or reactions among groups, with all severe events related to acute stroke recurrence and no fatalities reported [1] - Zhilong Tongluo Pian demonstrated effectiveness in improving the Rankin scale for disability, enhancing neurological function, and increasing daily living capabilities [1] Group 2: Efficacy and Recommendations - The drug is effective for symptoms related to blood stasis and Qi deficiency, including upper limb paralysis and speech issues, with a trend towards efficacy in lower limb paralysis and other symptoms [1] - Both low-dose and high-dose groups showed comparable efficacy, with a recommendation to continue Phase III clinical research for the low-dose group [1]